• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA approves ALOXI for pediatric, chemotherapy-induced nausea

FDA approves ALOXI for pediatric, chemotherapy-induced nausea

May 29, 2014
CenterWatch Staff

Eisai and Helsinn Group have announced the FDA approval of ALOXI (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged one month to less than 17 years.

This is the first approval of a product for acute chemotherapy-induced nausea and vomiting (CINV) prevention in patients aged one month to six months. The age of peak cancer incidence among children occurs within the first year of life, so this approval offers an important option to children, and especially infants, undergoing chemotherapy. CINV is among the most common side effects following therapy in patients with cancer. In clinical trials, CINV has been seen in 35%-80% of pediatric patients.

"The prevention of nausea and vomiting induced by chemotherapy remains an unmet need in children, despite available therapies," said Riccardo Braglia, CEO, Helsinn Group. "This approval provides access to a new treatment option for CINV prevention."

Helsinn conducted four pediatric clinical trials with ALOXI. The approval was based on a randomized, double-blind, non-inferiority pivotal trial comparing single-dose intravenous (IV) ALOXI 20mcg/kg given 30 minutes prior to chemotherapy to a standard of care IV ondansetron regimen of 0.15mg/kg given 30 minutes prior to chemotherapy followed by infusions four and eight hours after the first dose of ondansetron. Within the first 24 hours after chemotherapy, complete response, defined as no vomiting, no retching and no antiemesis rescue medication, was achieved in 59.4% of patients who received ALOXI 20mcg/kg versus 58.6% of those who received the ondansetron regimen. This demonstrated that single-dose ALOXI met its primary endpoint.

Treatment-emergent adverse events (TEAEs) were comparable across both arms, with the most frequently reported TEAE in the palonosetron group being headaches. While this study demonstrated that pediatric patients require a higher palonosetron dose than adults to prevent CINV, the safety profile is consistent with the established profile in adults.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing